When Patient-Reported Outcomes Could Pose Risks
During a recent conference on quality of life in patients with cancer, FDA-affiliated researchers debunked a notion about biases — but raised some concerns about PROs.
Multiple Myeloma
MULTIPLE MYELOMA ADVISOR
FEATURED CONTENT
-
-
How to Help Patients With Cancer Find Trustworthy Information Online
Patients may find misinformation on websites or social media forums, but doctors can help by recommending reliable sources. -
Gender Bias in Oncology: Q&A With Dr Narjust Duma
Women are less likely to be introduced by their professional title and most likely to be introduced by first name. -
Can CAR-T Be Optimized for Multiple Myeloma?
To tweak CAR-T therapies for myeloma, researchers are trying to repurpose a failed Alzheimer’s drug and are extracting patients’ T cells sooner. -
FDA Proposal Threatens Transparency on Cancer Drug Safety and Efficacy
FDA documents have been a trove of information for researchers, leading to new insights about the safety and efficacy of a drug. An FDA proposal could end that.
VIDEO SERIES
MULTIPLE MYELOMA NEWS
Evidence of Clinical Benefit for Bispecific Antibody in Patients With Refractory Multiple Myeloma
Circulating Tumor Plasma Cells Predict Progression in Myeloma
Chromosomal Aberrations in Clones Seem Prognostic in Smoldering Myeloma
MPN-Directed Therapy Does Not Alter Timing of Clinical Manifestations of Splanchnic Vein Thrombosis
Antibiotic Prophylaxis Reduced Febrile Episodes, Death in Newly Diagnosed Myeloma in TEAMM Trial
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma
